Pfizer (PFE) : Pettee Investors reduced its stake in Pfizer by 16.51% during the most recent quarter end. The investment management company now holds a total of 148,185 shares of Pfizer which is valued at $4.9 Million after selling 29,300 shares in Pfizer , the firm said in a disclosure report filed with the SEC on May 11, 2016.Pfizer makes up approximately 4.97% of Pettee Investors’s portfolio.
Other Hedge Funds, Including , Capwealth Advisors boosted its stake in PFE in the latest quarter, The investment management firm added 358 additional shares and now holds a total of 1,312 shares of Pfizer which is valued at $43,545. Pfizer makes up approx 0.01% of Capwealth Advisors’s portfolio. Howard Hughes Medical Institute added PFE to its portfolio by purchasing 10,541 company shares during the most recent quarter which is valued at $349,856. Pfizer makes up approx 0.08% of Howard Hughes Medical Institute’s portfolio.Capital Advisors Incok boosted its stake in PFE in the latest quarter, The investment management firm added 281,497 additional shares and now holds a total of 301,440 shares of Pfizer which is valued at $10.1 Million. Pfizer makes up approx 1.63% of Capital Advisors Incok’s portfolio.Cadence Capital Management reduced its stake in PFE by selling 18,712 shares or 4.64% in the most recent quarter. The Hedge Fund company now holds 384,515 shares of PFE which is valued at $12.9 Million. Pfizer makes up approx 0.90% of Cadence Capital Management’s portfolio.Sanders Morris Harris boosted its stake in PFE in the latest quarter, The investment management firm added 22,357 additional shares and now holds a total of 34,641 shares of Pfizer which is valued at $1.1 Million. Pfizer makes up approx 0.19% of Sanders Morris Harris’s portfolio.
Pfizer opened for trading at $32.93 and hit $33.43 on the upside on Monday, eventually ending the session at $33.38, with a gain of 0.57% or 0.19 points. The heightened volatility saw the trading volume jump to 2,20,48,594 shares. Company has a market cap of $202,445 M.
On the company’s financial health, Pfizer reported $0.67 EPS for the quarter, beating the analyst consensus estimate by $ 0.12 according to the earnings call on May 3, 2016. Analyst had a consensus of $0.55. The company had revenue of $13005.00 million for the quarter, compared to analysts expectations of $12008.32 million. The company’s revenue was up 19.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.51 EPS.
Many Wall Street Analysts have commented on Pfizer. Berenberg Initiated Pfizer on May 12, 2016 to “Hold”, Price Target of the shares are set at $38.Company shares were Reiterated by UBS on May 4, 2016 to “Buy”, Firm has raised the Price Target to $ 38 from a previous price target of $36 .Goldman Resumed Pfizer on Apr 18, 2016 to “Neutral”, Price Target of the shares are set at $35.
Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.